Clinical evaluation of valsartan and metoprolol tartrate in treatment of diabetic nephropathy with positive β1-adrenergic and anti-angiotensin II type 1 receptor antibody

Chinese Medical Journal

Volumn 125, Issue 19, 2012, Pages 3543-3547

  Zhao, Lin shuang ^a   Bai, Wei wei ^a   Xiang, Guang da ^a   Yue, Ling ^a   Sun, Hui ling ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

1 adrenergic receptor; Anti angiotensin II type 1 receptor; Diabetic nephropathy; Metoprolol tartrate; Valsartan

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR; AUTOANTIBODY; BETA 1 ADRENERGIC RECEPTOR; CREATININE; CYSTATIN C; FUROSEMIDE; METOPROLOL TARTRATE; NITRENDIPINE; VALSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERKALEMIA; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; PROTEINURIA; TURBIDIMETRY; UREA NITROGEN BLOOD LEVEL;

AGED; AUTOANTIBODIES; DIABETIC NEPHROPATHIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; METOPROLOL; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ADRENERGIC, BETA-1; TETRAZOLES; VALINE;

EID: 84867433238     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.19.033     Document Type: Article

References (33)

1. Bansal G, Divietro JA, Kuehn HS, Rao S, Nockal KH, Gilfillan AM, et al. RGS13 controls GPCR-evoked responses of human mast cell. J Immmunol 2008; 181: 7882-7890.
2. Felix SB, Staudt A, Landsberger M, Grosse Y, Stangl V, Spielhagen T, et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 2002; 39: 646-652.
3. Gouwy M, Struyf S, Verbeke H, Proost P, Opdenakker G, van Damme J. CC chemokine ligand2 synergize with the nonchemokine G protein-coupled receptor ligand fMLP in monocyte chemotaxis, and it cooperates with the TLR ligand LPS via induction of CXCL8. Leukoc Biol 2009; 86: 671-680.
4. Almeida JC, Zelmanovitz T, Vaz JS, Steemburgo T, Perassolo MS, Gross JL, et al. Sources of protein and polyunsaturated fatty acids of the diet and microalbuminuria in type 2 diabetes mellitus. J Am Coll Nutr 2008; 27: 528-537.
5. Fioretto P, Caramori ML, Mauer M. The kidney in diabetes: dynamic pathways of injury and repair. The camillo Golgi Lecture 2007. Diabetologia 2008; 51: 1347-1355.
6. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221-226.
7. Leitao CB, Canani LH, Polson PB, Molon MP, Piontti AF, Gress JL. Urinary albumin excretion rate is associated with increased ambulatory blood pressure in normoalbuminuric type 2 diabetic patients. Diabetes Care 2005; 28: 1724-1729.
8. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephrophthy: diagnosis, prevention, and treatment. Diabetes Care 2005; 28: 164-176.
9. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
10. Fu ML, Herlitz H, Schulze W, Wallukat G, Micke P, Eftekhari P, et al. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens 2000; 18: 945-953.
11. Jahns R, Boivin V, Siegmund C, Boege F, Lohse MJ, Inselmann G. Activating β-1-adrenoceptor antibodies are not associated with cardiomyopathies secondary to valvular or hypertensive heart disease. J Am Coll Cardiol 1999; 34: 1545-1551.
12. Wallukat G, Muller J, Hetzer R. Specific removal of β1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med 2002; 347: 1806.
13. Zhou ZH, Liao YH, Li LD, Wang B, Wei F, Wang M, et al. Immune mechanism of cardiac remodeling induced by antibodies against to the α1-adrenergic receptor. Chin Med J 2005; 85: 625-629.
14. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354: 131-140.
15. Viberti GC, Bilous RW, Mackintosh D, Keen H. Monitoring glomerular function in diabetic nephropathy: A prospective study. Am J Med 1983; 74: 256-264.
16. Hegar JR, Bigler SA, Henegar LK, Tyagy SC, Hall JE. Functional and structural changes in the kiney in the early stages of obesity. J Am Soc Nephrol 2001; 12: 1211-1217.
17. Sarafidis PA, Stafylas PC, Kanaki AI, Lasaridis AN. Effects of reninangiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis. Am J Hypertens 2008; 21: 922-929.
18. Schimke I, Muller J, Priem F, Kruse I, Schon B, Stein J, et al. Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption. J Am Coll Cardiol 2001; 38: 178-183.
19. Wallukat G, Muller J, Podlowski S, Nissen E, Morwinski R, Hetzer R. Agonist-like β-adrenoceptor antibodies in heart failure. Am J Cardiol 1999; 83: 75H-79H.
20. Dzielak DJ. Immune mechanisms in experimental and essential hypertension. Am J Physiol 1991; 260: R459-R467.
21. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
22. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
23. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesaratan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
24. Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009; 4: 361-368.
25. Parving HH, persson F, Lewis EJ, Hollenberg NK. Aliskren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446.
26. Shan JS, Wilmot RL, Kipatrick ES. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med 2007; 24: 1160-1163.
27. Iglesias P, Dize JJ. Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur J Endocrinol 2006; 154: 613-621.
28. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180: 32-39.
29. Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptidyl peptidase-4 inhibitor. Diabetes Care 2007; 30: 1862-1864.
30. Pan Y, Guo LL, Jin HM. Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2008; 88: 660-666.
31. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Livingstone SJ, Charlton-menys V, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes study (CARDS). Am J Kidney Dis 2009; 54: 810-819.
32. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996; 334: 1649-1654.
33. Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010; 122: 844-846.